These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 7514051)

  • 21. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors.
    Traycoff CM; Srour EF; Dutt P; Fan Y; Cornetta K
    Leukemia; 1997 Jan; 11(1):159-67. PubMed ID: 9001433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P; Cornetta K; Davidson A; Agüero B; McMahel J; Traycoff CM; Srour EF
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous bone marrow transplantation for CML in which retroviral markers are used to discriminate between relapse which arises from systemic disease remaining after preparative therapy versus relapse due to residual leukemia cells in autologous marrow: a pilot trial. The University of Texas M.D. Anderson Cancer Center.
    Hum Gene Ther; 1991; 2(4):359-76. PubMed ID: 1665350
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL; Timson L; Kawasaki ES; Clark SS; Witte ON; Champlin R
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):563-7. PubMed ID: 2405384
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of genetic markers in chronic myelogenous leukemia patients after bone marrow transplantation.
    Zámecníková A; Kri an P; Mistrík M
    Neoplasma; 2000; 47(5):299-302. PubMed ID: 11130247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow.
    Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
    Blood; 1999 Jul; 94(2):384-9. PubMed ID: 10397704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged remission and autologous recovery in two patients with chronic myelogenous leukemia after graft failure of allogeneic bone marrow transplantation.
    Fouillard L; Deconinck E; Tiberghien P; Deschaseaux ML; Solary E; Mugneret F; Brion A; Herve P; Cahn JY
    Bone Marrow Transplant; 1998 May; 21(9):943-6. PubMed ID: 9613789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytogenetic analysis of chimerism and leukemia relapse in chronic myelogenous leukemia patients after T cell-depleted bone marrow transplantation.
    Offit K; Burns JP; Cunningham I; Jhanwar SC; Black P; Kernan NA; O'Reilly RJ; Chaganti RS
    Blood; 1990 Mar; 75(6):1346-55. PubMed ID: 2310831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous bone marrow transplantation for leukemia.
    Stuart RK
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):40-54. PubMed ID: 8211215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Alyea EP; Soiffer RJ; Roy DC; Ritz J
    Blood; 1994 Oct; 84(7):2109-14. PubMed ID: 7919323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
    Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
    Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Autologous transplant for CML revisited.
    Daley GQ; Goldman JM
    Exp Hematol; 1993 Jun; 21(6):734-7. PubMed ID: 8500574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation.
    Eder M; Battmer K; Kafert S; Stucki A; Ganser A; Hertenstein B
    Leukemia; 1999 Sep; 13(9):1383-9. PubMed ID: 10482989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
    Snyder DS; Rossi JJ; Wang JL; Sniecinski IJ; Slovak ML; Wallace RB; Forman SJ
    Transplantation; 1991 May; 51(5):1033-40. PubMed ID: 1674385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.